CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy
Celia Cordero-Sánchez(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Armando A. Genazzani(University of Turin)
Cited by 12
Related Papers
Performance of the accelerated assessment of the European Medicines Agency
|British Journal of Clinical Pharmacology|2025|4
Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study
|Frontiers in Medicine|2025|2
L’accesso ai farmaci per malattie rare tra aspetti regolatori e priorità di salute pubblica
|Recenti Progressi in Medicina|2022|1